Expanding the Value Metrics in Fixed-Budget Healthcare Systems

By Staff Writer

August 20, 2024

Introduction

Traditional cost-effectiveness analysis (CEA) has long been a cornerstone in healthcare decision-making. However, its reliance on measures like quality-adjusted life-years (QALYs) has faced criticism for excluding additional value dimensions. A recent publication addresses this gap by exploring extra-welfarist (EW) methods to incorporate values beyond just health. The focus was on non-market environments, such as the British National Health Service (BNHS) and similar systems worldwide.

Limitations of Traditional CEA

CEA typically combines health-related quality of life and life expectancy into QALYs, which are then compared with associated costs. This method relies solely on individual utility measures. Similar criticisms apply to EW methods, which avoid using individual utility preferences but still focus predominantly on health. Despite its intent to include broader values, EW has not effectively incorporated gains beyond health due to a lack of clear methodologies.

Expanding Value Metrics in Healthcare

The ISPOR 2018 Task Force introduced the “Value Flower,” which catalogues potential missing value sources. These include health-related gains like productivity, real option value, reduced caregiver burden, and health equity. For example, improved health can decrease caregiver burden, measured by the rate at which burden declines as patient health improves. Table 1 provides examples of these additional values and their measurement methods. These value elements can be characterised as improvement in people’s health or depend on treatment severity.

Table 1. Examples of Health-Related Additional Values and Their Measurement

Budget Allocations and Willingness to Pay (WTP)

The ability to supply additional health comes at increasing marginal cost, influenced by available technologies and their application. Optimality is achieved when marginal cost equals WTP. For example, the BNHS budget for 2022/23 was £181.7 billion. The operative threshold for cost-effectiveness in the UK is closer to £13,000 per QALY, despite higher advertised values. This discrepancy highlights the importance of budget allocations in determining implicit WTP values.

Challenges and Solutions

Numerous conceptual problems remain in incorporating these additional values, such as double counting and assessing WTP. Double counting can be avoided through conceptualisation or statistical analysis. For instance, worker productivity and absenteeism often overlap. Professional judgement is crucial in these cases to ensure accurate valuation without redundancy.

Conclusion

When EW proponents aim to use measures other than individual utility, the only meaningful substitute becomes decision-makers’ willingness to increase healthcare budgets. This approach highlights the importance of societal values and the distribution of benefits. In fixed-budget environments, only the commitment of governments or major non-governmental organisations to fund these extra values can bring them to fruition. When we move from “health” to “welfare” in the measurement of increased healthcare value, we can develop methods with additional values that are truly expanding value metrics in healthcare.

 

 

Reference url

Recent Posts

EU Life Sciences Strategy
         

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?

The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.

Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #Innovation

ticagrelor data integrity
          

Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials

🔍 Are we truly getting the full story on high-cost medications like ticagrelor?

A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.

Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.

#SyenzaNews #HealthEconomics #Pharmaceuticals #MarketAccess

self-care public health
    

The Value of Self-Care in Public Health: Insights and Implications for Europe

🌍 Are we overlooking the power of self-care in Europe’s public health strategy?

The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.

Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.